Research group Kristina Broliden

Denna sida på svenska

Kristina Broliden, Professor, Group Leader

Current position

Professor and Senior Consultant, Unit of Infectious Diseases, Karolinska Institutet and Clinic of Infectious Diseases, Karolinska University Hospital

Head of Department, Department of Medicine Solna, Karolinska Institutet

Professor/senior physician

Kristina Broliden

Phone: +46-(0)8-517 760 45
Organizational unit: Group Broliden
E-mail: Kristina.Broliden@ki.se

Adress

Karolinska Institutet
Institutionen för medicin, Solna
Enheten för infektionssjukdomar
171 76 Stockholm

Kristina Broliden Goup

The aim of the Broliden/Tjernlund team is to characterize genital mucosal barriers against HIV-infection.

 

The aim of the Broliden/Öhrmalm team is to characterize infections in immunosuppressed patients to improve antiviral and antibiotic treatment.

Team Annelie Tjernlund

GENITAL MUCOSAL BARRIERS AGAINST HIV-INFECTION

Environmental factors including hormonal contraceptive use, genital infections and seminal fluid itself affect the susceptibility to HIV infection as demonstrated in epidemiological and experimental studies. The molecular mechanisms behind these findings are however poorly defined. Our group aims to study how the human female genital tract is affected by these factors by assessing tissue samples and cervicovaginal secretions from large cohorts of Swedish and Kenyan women who are sexually exposed to HIV infection. Genital samples are defined by expression of junction proteins, distribution and density of HIV receptors and innate immune proteins by using immunohistochemistry, tissue explants models and proteomics. By exploring some of the underlying mechanisms for a dysfunctional mucosal barrier we hope to contribute to the development of topical prophylactic compounds and to the prescription of optimal contraceptive methods to women.

Environmental factors including hormonal contraceptive use, genital infections and seminal fluid itself affect the susceptibility to HIV infection as demonstrated in epidemiological and experimental studies. The molecular mechanisms behind these findings are however poorly defined. Our group aims to study how the human female genital tract is affected by these factors by assessing tissue samples and cervicovaginal secretions from large cohorts of Swedish and Kenyan women who are sexually exposed to HIV infection. Genital samples are defined by expression of junction proteins, distribution and density of HIV receptors and innate immune proteins by using immunohistochemistry, tissue explants models and proteomics. By exploring some of the underlying mechanisms for a dysfunctional mucosal barrier we hope to contribute to the development of topical prophylactic compounds and to the prescription of optimal contraceptive methods to women.

Team Lars Öhrmalm


INFECTIONS IN IMMUNOSUPPRESSED PATIENTS

Infections in patients with haematological disorders

Early diagnosis of severe virus infections in immunosuppressed patients has undergone major advances during recent years. Modern molecular techniques have resulted in reduction of morbidity and mortality associated with these infections. Through experimental and clinical studies on human parvovirus B19 infections, we have shown that this common infection can also result in severe morbidity and lethal complications. The clinical course and corresponding immune responses are defined in various patient categories. Clinical protocols and therapeutic interventions have been launched as a result of these studies. The clinical and scientific focus of these studies has also been broadened to include other respiratory tract infections in children and adults. We have here contributed to the knowledge of how to diagnose and initiate early treatment in these cases and which pathogens can be defined as etiological agents of the symptoms. Definition of etiological causes for severe complications in patients can result in better antiviral treatment options and development of not only antiviral compounds but also combination treatments including modern immunomodulatory drugs.

Infections during pregnancy

Parvovirus B19 is a pathogen that can cause severe and lethal fetal infections if the mother is infected during pregnancy. Together with our colleagues in gynecology and pathology we have developed better diagnostic tools and treatment options for these cases. We have also co-founded a national reference center that allows consultancies in urgent and complicated cases of both bacterial and viral infections during pregnancy. The overall information is available for both the public and health professionals in a widely spread and frequently used database that is up-dated monthly with new clinical and scientific information (www.infpreg.se). 

Infections in patients with respiratory tract diseases

Despite the use of established viral PCR methods, approximately 30% of all presumed viral respiratory tract infections are not detected with current methods. We have studied respiratory tract infections and how co-infections of virus and bacterial agents interact with the host immune response in the airway mucosa. For these studies our group has included healthy children with acute onset of severe respiratory tract infections, children suffering from asthmatic disorders and healthy control children.  The project now aims to improve diagnostics to distinguish viral from bacterial pneumonia and optimize treatment in patients with severe infections.  Mass spectrometry-based proteomic analyses are used as a promising method to assess host-microbe interaction in respiratory tract infections. Identifying mucosal biomarkers may provide a rapid, accurate and clinically useful test for early identification of patients with severe viral pneumonia. This is now explored in a number of ongoing clinical studies initiated by us as a result of our clinical activities.

Selected publications

In Situ Staining and Laser Capture Microdissection of Lymph Node Residing SIV Gag-Specific CD8+ T cells--A Tool to Interrogate a Functional Immune Response Ex Vivo.
Tjernlund A, Burgener A, Lindvall J, Peng T, Zhu J, Öhrmalm L, et al
PLoS ONE 2016 ;11(3):e0149907

Presence of rhinovirus in the respiratory tract of adolescents and young adults with asthma without symptoms of infection.
Öhrmalm L, Malinovschi A, Wong M, Levinson P, Janson C, Broliden K, et al
Respir Med 2016 06;115():1-6

Metagenomic analysis of bloodstream infections in patients with acute leukemia and therapy-induced neutropenia.
Gyarmati P, Kjellander C, Aust C, Song Y, Öhrmalm L, Giske C
Sci Rep 2016 Mar;6():23532

Improving Adherence to Post-Cervical Biopsy Sexual Abstinence in Kenyan Female Sex Workers.
Lajoie J, Boily-Larouche G, Doering K, Cheruiyot J, Oyugi J, Broliden K, et al
Am. J. Reprod. Immunol. 2016 07;76(1):82-93

Frequent Respiratory Viral Infections in Children with Febrile Neutropenia - A Prospective Follow-Up Study.
Söderman M, Rhedin S, Tolfvenstam T, Rotzén-Östlund M, Albert J, Broliden K, et al
PLoS ONE 2016 ;11(6):e0157398

Blood pressure regulation by CD4 lymphocytes expressing choline acetyltransferase.
Olofsson P, Steinberg B, Sobbi R, Cox M, Ahmed M, Oswald M, et al
Nat. Biotechnol. 2016 Oct;34(10):1066-1071

Innate Invariant NKT Cell Recognition of HIV-1-Infected Dendritic Cells Is an Early Detection Mechanism Targeted by Viral Immune Evasion.
Paquin-Proulx D, Gibbs A, Bächle S, Checa A, Introini A, Leeansyah E, et al
J. Immunol. 2016 09;197(5):1843-51

HIV-1-Neutralizing IgA Detected in Genital Secretions of Highly HIV-1-Exposed Seronegative Women on Oral Preexposure Prophylaxis.
Lund J, Broliden K, Pyra M, Thomas K, Donnell D, Irungu E, et al
J. Virol. 2016 Nov;90(21):9855-9861



;():

MAIT cells reside in the female genital mucosa and are biased towards IL-17 and IL-22 production in response to bacterial stimulation.
Gibbs A, Leeansyah E, Introini A, Paquin-Proulx D, Hasselrot K, Andersson E, et al
Mucosal Immunol 2017 01;10(1):35-45

Genital Injury Signatures and Microbiome Alterations Associated With Depot Medroxyprogesterone Acetate Usage and Intravaginal Drying Practices.
Birse K, Romas L, Guthrie B, Nilsson P, Bosire R, Kiarie J, et al
J. Infect. Dis. 2017 02;215(4):590-598

 

Contact

 

Administrator

Administrator

Anne Rasikari

Phone: +46-(0)8-517 718 61
Organizational unit: Group A Färnert
E-mail: Anne.Rasikari@ki.se

Adress:Institutionen för medicin, Solna (MedS), K2